{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:18:28.680Z","profile":{"slug":"octreotide","name":"Octreotide","aliases":[],"category":"Somatostatin analog"},"synthesis":{"mechanism":"Octreotide is a synthetic cyclic octapeptide analog of somatostatin with greater metabolic stability and longer action than endogenous somatostatin. It binds predominantly somatostatin receptor subtypes 2 and 5, suppressing growth hormone and several gastroenteropancreatic hormones and secretions; effects therefore vary by receptor expression, disease, route, and formulation. Immediate-release injection, depot injection, and delayed-release oral products have distinct pharmacokinetics and regulatory labeling.","evidence":"The governed 25-source corpus includes PROMID and long-term follow-up, carcinoid-syndrome and acromegaly formulation trials, oral and implant phase 3 programs, neuroendocrine-tumor combination research, gastrointestinal bleeding and malignant-obstruction trials, pancreatic-surgery studies, polycystic liver/kidney research, lymphatic transport, and a neonatal chylothorax systematic review. PubMed identity, titles, authorship, DOI/PMID, status, directness, and duplication were checked. Evidence lanes preserve randomized, observational, pharmacokinetic, systematic-review, and off-label contexts.","safety":"Gallstones and biliary complications, glucose dysregulation, gastrointestinal effects, bradycardia and conduction changes, thyroid alterations, nutritional effects, injection-site problems, and drug interactions require clinical context. Tumor receptor profile, secretory status, prior response, hepatic function, route, formulation, and administration timing affect benefit and exposure. Small trials, post hoc analyses, surrogate endpoints, and heterogeneous off-label populations limit generalization. Current product labeling—not this profile—controls indications, contraindications, preparation, monitoring, and use.","observationalBoundary":"Octreotide has established hormone-suppressive and symptom-control roles in selected acromegaly and functional neuroendocrine-tumor settings; PROMID also informs tumor-growth control in metastatic midgut neuroendocrine tumors. Evidence for bleeding, fistula, pancreatitis, bowel obstruction, polycystic disease, chylothorax, transplant, and lymphatic indications is heterogeneous and often investigational or off-label. Formulation evidence is not automatically transferable across subcutaneous, depot, implant, or oral delivery. Comparator and combination trials are interpreted only within their tested regimens.","openQuestions":"Which biomarkers best predict symptomatic and antiproliferative response across neuroendocrine-tumor subtypes? How should octreotide be sequenced with lanreotide, targeted agents, surgery, and peptide-receptor radionuclide therapy? Which patients can transition safely among injectable, depot, implant, and oral formulations? What are the long-term comparative metabolic, biliary, cardiac, and quality-of-life outcomes? Which bleeding, lymphatic, pancreatic, and bowel-obstruction uses merit adequately powered trials, and which should be abandoned after neutral evidence?"},"completion":{"version":"wpf-profile-v1.0","complete":false,"checks":[{"key":"overview","passed":true,"actual":514,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":599,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":621,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":614,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":572,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["reviewed_sources","claims"]},"chemistry":{"id":"9060357fe9fd9f3bd499bd79130f6d2b","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","molecularFormula":"C49H66N10O10S2","molecularWeight":1019.2,"aminoAcidSequence":"[D-Phe]-Cys-Phe-[D-Trp]-Lys-Thr-Cys-Thr-ol; Cys2-Cys7 disulfide","smiles":"C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O","inchi":"InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1","inchikey":"DEQANNDTNATYII-OULOTJBUSA-N","structureImageUrl":"https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/448601/PNG","createdAt":"2026-09-09T22:54:49.060Z","updatedAt":"2026-09-09T22:54:49.060Z"},"evidence":[{"id":"baabcb30d5505b4fb513858351f4a75b","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40418492/","evidenceTier":"phase_3","summary":"Octreotide is a first-generation somatostatin receptor ligand (SRL) approved for acromegaly treatment.","authors":"Anaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, Anna Hansson, Markus Johnsson, Fredrik Tiberg","publishingOrg":"Clinical pharmacokinetics","publicationYear":2025,"doi":"10.1007/s40262-025-01522-3","pubmedId":"40418492","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40262-025-01522-3","sourceIdentityId":"e86a45c7b51e60bc6df6146ca3eda2ed","sourceStatus":"active","sourceContentHash":"63e5465a964f3bffdebf186a66b017f19e10f73f698e924e5f035f6337e76e81","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:40418492","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s40262-025-01522-3","locator":"https://pubmed.ncbi.nlm.nih.gov/40418492/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"63e5465a964f3bffdebf186a66b017f19e10f73f698e924e5f035f6337e76e81","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"40418492","rawPayloadReference":"pubmed:40418492"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"f25ea0a9b960a61eb9ab1b57ef16c4a4","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Octreotide improves human lymphatic fluid transport a translational trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37951584/","evidenceTier":"phase_1_2","summary":"Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment.","authors":"Thomas Holm-Weber, Frederik Skov, Sheyanth Mohanakumar, Lene Thorup, Troels Riis, Mikkel Bring Christensen, David Peick Sonne, Per Bo Jensen, Donna Briggs Bødtkjer, Vibeke Elisabeth Hjortdal","publishingOrg":"European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery","publicationYear":2024,"doi":"10.1093/ejcts/ezad380","pubmedId":"37951584","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1093/ejcts/ezad380","sourceIdentityId":"2e986d6eaf76a842c51adbf6fe2bed8a","sourceStatus":"active","sourceContentHash":"be9d820a061fe918f55a2e0137852629aab43261590e7619710b2ed033f18f3c","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:37951584","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1093/ejcts/ezad380","locator":"https://pubmed.ncbi.nlm.nih.gov/37951584/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"be9d820a061fe918f55a2e0137852629aab43261590e7619710b2ed033f18f3c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"37951584","rawPayloadReference":"pubmed:37951584"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"dbdb484faca4f597d117ca59783d9a1e","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38662619/","evidenceTier":"phase_1_2","summary":"Pharmacological prevention of postoperative pancreatic fistula (POPF) after pancreatectomy is open to debate.","authors":"Sébastien Gaujoux, Jean-Marc Regimbeau, Guillaume Piessen, Stéphanie Truant, Frantz Foissac, Louise Barbier, Emmanuel Buc, Mustapha Adham, David Fuks, Sophie Deguelte, Fabrice Muscari, Laurent Sulpice","publishingOrg":"Annals of surgery","publicationYear":2024,"doi":"10.1097/sla.0000000000006313","pubmedId":"38662619","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1097/sla.0000000000006313","sourceIdentityId":"7a521ed3c68d47e65f5232f3b2bd2cc9","sourceStatus":"active","sourceContentHash":"df6887df3ae19537f952ce2ed4090640f269daf5e6efccce0601d44281c48dab","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:38662619","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1097/SLA.0000000000006313","locator":"https://pubmed.ncbi.nlm.nih.gov/38662619/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"df6887df3ae19537f952ce2ed4090640f269daf5e6efccce0601d44281c48dab","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"38662619","rawPayloadReference":"pubmed:38662619"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"15736290ea087d391f8d8ef4274f67bc","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38158089/","evidenceTier":"phase_1_2","summary":"Gastrointestinal angiodysplasias are vascular anomalies that may result in transfusion-dependent anemia despite endoscopic therapy.","authors":"Lia C M J Goltstein, Karina V Grooteman, Lucas H P Bernts, Robert C H Scheffer, Robert J F Laheij, Lennard P L Gilissen, Ruud W M Schrauwen, Nynke C Talstra, Abraham T Zuur, Henri Braat, Muhammed Hadithi, Johannes T Brouwer","publishingOrg":"Gastroenterology","publicationYear":2024,"doi":"10.1053/j.gastro.2023.12.020","pubmedId":"38158089","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1053/j.gastro.2023.12.020","sourceIdentityId":"141bb7bcfe118ee5a6b4e778eadf094a","sourceStatus":"active","sourceContentHash":"5344522183e802571387f0c267f5e42f9798c3b7ca906a37ebf63baa890c3818","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:38158089","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1053/j.gastro.2023.12.020","locator":"https://pubmed.ncbi.nlm.nih.gov/38158089/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"5344522183e802571387f0c267f5e42f9798c3b7ca906a37ebf63baa890c3818","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"38158089","rawPayloadReference":"pubmed:38158089"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"9214cdc3a3175d8604ebd7849e8e1b0d","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/35867022/","evidenceTier":"phase_1_2","summary":"Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant.","authors":"Kamran Bagheri Lankarani, Hoda Safa, Sulmaz Ghahramani, Mohammad Sayari, Seyed-Ali Malekhosseini","publishingOrg":"Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","publicationYear":2022,"doi":"10.6002/ect.2022.0080","pubmedId":"35867022","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.6002/ect.2022.0080","sourceIdentityId":"5bbbf1099257e48da28d1eff40cd9f01","sourceStatus":"active","sourceContentHash":"c63d4346128b0d360da0c96ba0060980aae1a1a7cb0ed6c72d9bb8e37d239374","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:35867022","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.6002/ect.2022.0080","locator":"https://pubmed.ncbi.nlm.nih.gov/35867022/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"c63d4346128b0d360da0c96ba0060980aae1a1a7cb0ed6c72d9bb8e37d239374","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"35867022","rawPayloadReference":"pubmed:35867022"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"f345f4992b2f14add665d71883e48092","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34173129/","evidenceTier":"phase_3","summary":"Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.","authors":"Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gordon, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam","publishingOrg":"Pituitary","publicationYear":2021,"doi":"10.1007/s11102-021-01163-2","pubmedId":"34173129","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s11102-021-01163-2","sourceIdentityId":"f1952be1da6eebbadb96571ddb3aa498","sourceStatus":"active","sourceContentHash":"cddb32012d099fd639a81269a9137ee913648534ece57dcf966493843eb23d52","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:34173129","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s11102-021-01163-2","locator":"https://pubmed.ncbi.nlm.nih.gov/34173129/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"cddb32012d099fd639a81269a9137ee913648534ece57dcf966493843eb23d52","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"34173129","rawPayloadReference":"pubmed:34173129"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"64fa41ce5a3213770207efc36ef64e63","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Octreotide for congenital and acquired chylothorax in newborns: A systematic review.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/29602276/","evidenceTier":"observational","summary":"Chylothorax is a rare but life-threatening condition in newborns.","authors":"Carlo Bellini, Rita Cabano, Laura C De Angelis, Tommaso Bellini, Maria G Calevo, Paolo Gandullia, Luca A Ramenghi","publishingOrg":"Journal of paediatrics and child health","publicationYear":2018,"doi":"10.1111/jpc.13889","pubmedId":"29602276","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/jpc.13889","sourceIdentityId":"e84371cf4568d64acafde250a6294f47","sourceStatus":"active","sourceContentHash":"08468c1febee05105d23341fc7737d908fc52f8e9b54614e618265b2fe7906bf","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:29602276","evidenceLane":"meta_analysis","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review and meta-analysis","sourceStrength":{"grade":"A","score":88,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":88,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1111/jpc.13889","locator":"https://pubmed.ncbi.nlm.nih.gov/29602276/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"08468c1febee05105d23341fc7737d908fc52f8e9b54614e618265b2fe7906bf","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"29602276","rawPayloadReference":"pubmed:29602276"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"f91bf70443e62f2f348983cc98c20d25","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26731483/","evidenceTier":"phase_1_2","summary":"Somatostatin analogs have been shown to control the growth of well-differentiated metastatic neuroendocrine tumors.","authors":"Anja Rinke, Michael Wittenberg, Carmen Schade-Brittinger, Behnaz Aminossadati, Erdmuthe Ronicke, Thomas M Gress, Hans-Helge Müller, Rudolf Arnold, PROMID Study Group","publishingOrg":"Neuroendocrinology","publicationYear":2017,"doi":"10.1159/000443612","pubmedId":"26731483","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1159/000443612","sourceIdentityId":"0e97682fb537c3670b9d01d8d9f82894","sourceStatus":"active","sourceContentHash":"9d2bc8c8a926f87391420d99af6b8dab999f788afdcea13188d4478e7c312fe2","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26731483","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1159/000443612","locator":"https://pubmed.ncbi.nlm.nih.gov/26731483/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"9d2bc8c8a926f87391420d99af6b8dab999f788afdcea13188d4478e7c312fe2","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26731483","rawPayloadReference":"pubmed:26731483"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"01805eeefcd361fbcec45aaedf885032","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25462210/","evidenceTier":"phase_1_2","summary":"Does octreotide reduce vomiting in cancer-associated bowel obstruction?","authors":"David C Currow, Stephen Quinn, Meera Agar, Belinda Fazekas, Janet Hardy, Nikki McCaffrey, Simon Eckermann, Amy P Abernethy, Katherine Clark","publishingOrg":"Journal of pain and symptom management","publicationYear":2015,"doi":"10.1016/j.jpainsymman.2014.09.013","pubmedId":"25462210","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jpainsymman.2014.09.013","sourceIdentityId":"066a8a6bfd2866e4a2e81b3331bfdd7e","sourceStatus":"active","sourceContentHash":"5a20b0ff095ae7d9dca2caf51d8ba6d5fa9b05d46a352a3e6fbc2f66c0df5a22","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:25462210","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.jpainsymman.2014.09.013","locator":"https://pubmed.ncbi.nlm.nih.gov/25462210/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"5a20b0ff095ae7d9dca2caf51d8ba6d5fa9b05d46a352a3e6fbc2f66c0df5a22","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"25462210","rawPayloadReference":"pubmed:25462210"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"a3edcd16df731b1d592d7c102c9b3736","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26373569/","evidenceTier":"phase_3","summary":"Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET).","authors":"Jonathan R Strosberg, James C Yao, Emilio Bajetta, Mounir Aout, Bert Bakker, John D Hainsworth, Philippe B Ruszniewski, Eric Van Cutsem, Kjell Öberg, Marianne E Pavel","publishingOrg":"Endocrine-related cancer","publicationYear":2015,"doi":"10.1530/erc-15-0314","pubmedId":"26373569","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1530/erc-15-0314","sourceIdentityId":"b6ec6fd446fb695664903e3e78499c2e","sourceStatus":"active","sourceContentHash":"4d8cb58ae00a057e0c6b5dc1a75f96232e1aa4f0c32e37e1e80be0aa5e586160","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26373569","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1530/ERC-15-0314","locator":"https://pubmed.ncbi.nlm.nih.gov/26373569/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"4d8cb58ae00a057e0c6b5dc1a75f96232e1aa4f0c32e37e1e80be0aa5e586160","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26373569","rawPayloadReference":"pubmed:26373569"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"cd77836a339625c7bf92d575b2aefd48","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25889313/","evidenceTier":"phase_1_2","summary":"The aim of this randomized controlled study was to determine whether octreotide (OCT) or scopolamine butylbromide (SB) was the more effective antisecretive drug controlling gastrointestinal (GI) symptoms due to malignant bowel obstruction (MBO) caused by advanced ovarian cancer.","authors":"Xingang Peng, Peige Wang, Shikuan Li, Guangyong Zhang, Sanyuan Hu","publishingOrg":"World journal of surgical oncology","publicationYear":2015,"doi":"10.1186/s12957-015-0455-3","pubmedId":"25889313","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1186/s12957-015-0455-3","sourceIdentityId":"293cab2606364ecf9fdc32e2b3bc61ad","sourceStatus":"active","sourceContentHash":"d54535a3a81e4af47e34cac203745808b56766a4bf609992eef4020a512013c1","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:25889313","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1186/s12957-015-0455-3","locator":"https://pubmed.ncbi.nlm.nih.gov/25889313/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"d54535a3a81e4af47e34cac203745808b56766a4bf609992eef4020a512013c1","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"25889313","rawPayloadReference":"pubmed:25889313"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"8ad12db137b021e837fae9fb7d3acc92","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25644760/","evidenceTier":"phase_1_2","summary":"Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment.","authors":"Marta Cavallin, Patrick S Kamath, Manuela Merli, Silvano Fasolato, Pierluigi Toniutto, Francesco Salerno, Mauro Bernardi, Roberto Giulio Romanelli, Cosimo Colletta, Freddy Salinas, Antonio Di Giacomo, Lorenzo Ridola","publishingOrg":"Hepatology (Baltimore, Md.)","publicationYear":2015,"doi":"10.1002/hep.27709","pubmedId":"25644760","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/hep.27709","sourceIdentityId":"cde57a89db5b156588f17147a2553830","sourceStatus":"active","sourceContentHash":"52cb871f75e1ceb73a7e1a001b8dbda26c03dbd628a9fb1fedddd0a4a3779f04","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:25644760","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1002/hep.27709","locator":"https://pubmed.ncbi.nlm.nih.gov/25644760/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"52cb871f75e1ceb73a7e1a001b8dbda26c03dbd628a9fb1fedddd0a4a3779f04","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"25644760","rawPayloadReference":"pubmed:25644760"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"4701ebe10c98d9135f5b46140e821928","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/23969184/","evidenceTier":"phase_3","summary":"Acromegaly is caused by excessive GH secretion and IGF-I overproduction.","authors":"Carla Chieffo, David Cook, Qinfang Xiang, Lawrence A Frohman","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2013,"doi":"10.1210/jc.2013-2262","pubmedId":"23969184","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2013-2262","sourceIdentityId":"134b386b3c3564b9612866b47a39d9ac","sourceStatus":"active","sourceContentHash":"eb22f9ce7262b29a6fbb0688fd0b2df7bd2e8e75a0aa1b12ccce8d2f5725b2d8","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:23969184","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2013-2262","locator":"https://pubmed.ncbi.nlm.nih.gov/23969184/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"eb22f9ce7262b29a6fbb0688fd0b2df7bd2e8e75a0aa1b12ccce8d2f5725b2d8","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"23969184","rawPayloadReference":"pubmed:23969184"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"fc28879d16ccb07f3c3186a103f9b340","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/21521254/","evidenceTier":"phase_1_2","summary":"Treatment with somatostatin analogues is the primary medical treatment of acromegaly.","authors":"Sven M Carlsen, Johan Svartberg, Thomas Schreiner, Sylvi Aanderud, Oivind Johannesen, Svein Skeie, Morten Lund-Johansen, Stine L Fougner, Jens Bollerslev, POTA study group","publishingOrg":"Clinical endocrinology","publicationYear":2011,"doi":"10.1111/j.1365-2265.2011.03982.x","pubmedId":"21521254","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/j.1365-2265.2011.03982.x","sourceIdentityId":"85cfff1ea447c27675d60e8917b28bdb","sourceStatus":"active","sourceContentHash":"ccdd22988f1cf02c80ba58f5cca2c58698420e2907bb81a27684ab58bdcfa14c","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:21521254","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1111/j.1365-2265.2011.03982.x","locator":"https://pubmed.ncbi.nlm.nih.gov/21521254/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"ccdd22988f1cf02c80ba58f5cca2c58698420e2907bb81a27684ab58bdcfa14c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"21521254","rawPayloadReference":"pubmed:21521254"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"d16a61819d613a78aee2e250bbfe38b1","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/20431041/","evidenceTier":"phase_1_2","summary":"There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD).","authors":"Marie C Hogan, Tetyana V Masyuk, Linda J Page, Vickie J Kubly, Eric J Bergstralh, Xujian Li, Bohyun Kim, Bernard F King, James Glockner, David R Holmes, Sandro Rossetti, Peter C Harris","publishingOrg":"Journal of the American Society of Nephrology : JASN","publicationYear":2010,"doi":"10.1681/asn.2009121291","pubmedId":"20431041","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1681/asn.2009121291","sourceIdentityId":"a6ac1b8b2779ead015ac7df4a5775950","sourceStatus":"active","sourceContentHash":"06201fec8edd693f30fcc21f5529b5fd46fcc25372d789b1ef91f87fee7933f7","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:20431041","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":70,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1681/ASN.2009121291","locator":"https://pubmed.ncbi.nlm.nih.gov/20431041/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"06201fec8edd693f30fcc21f5529b5fd46fcc25372d789b1ef91f87fee7933f7","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"20431041","rawPayloadReference":"pubmed:20431041"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"8754f41a85763f38772ed0bb0d4b4772","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/20185596/","evidenceTier":"phase_1_2","summary":"No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD).","authors":"Anna Caroli, Luca Antiga, Mariateresa Cafaro, Giorgio Fasolini, Andrea Remuzzi, Giuseppe Remuzzi, Piero Ruggenenti","publishingOrg":"Clinical journal of the American Society of Nephrology : CJASN","publicationYear":2010,"doi":"10.2215/cjn.05380709","pubmedId":"20185596","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2215/cjn.05380709","sourceIdentityId":"7bb0a9affbd248646c26834be511d670","sourceStatus":"active","sourceContentHash":"b69218970fc2935616ca47780c97805380ff694b039d39185ff421222ed3f83a","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:20185596","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.2215/CJN.05380709","locator":"https://pubmed.ncbi.nlm.nih.gov/20185596/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"b69218970fc2935616ca47780c97805380ff694b039d39185ff421222ed3f83a","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"20185596","rawPayloadReference":"pubmed:20185596"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"8fefbdefc8b818de66af95f30a75310b","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19704057/","evidenceTier":"phase_3","summary":"Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs).","authors":"Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold","publishingOrg":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","publicationYear":2009,"doi":"10.1200/jco.2009.22.8510","pubmedId":"19704057","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1200/jco.2009.22.8510","sourceIdentityId":"68929d913d573a9e687db3684697be4e","sourceStatus":"active","sourceContentHash":"33137ab9a3dd6757b8efe291a59212d606b1e38224e4a23fbd343544ed9a1045","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:19704057","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1200/JCO.2009.22.8510","locator":"https://pubmed.ncbi.nlm.nih.gov/19704057/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"33137ab9a3dd6757b8efe291a59212d606b1e38224e4a23fbd343544ed9a1045","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"19704057","rawPayloadReference":"pubmed:19704057"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"19537a693cc4feba2c5444fdcbad38c3","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19102400/","evidenceTier":"phase_1_2","summary":"The postoperative morbidity following pancreaticoduodenectomy (PD) remains very high.","authors":"Jean Closset, Stephane Journe, Freddy Mboti, Issam El Nakadi, Michel Gelin","publishingOrg":"Hepato-gastroenterology","publicationYear":2008,"doi":null,"pubmedId":"19102400","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:19102400","sourceIdentityId":"a71527fa5b04da74f4b63d4a324682cf","sourceStatus":"active","sourceContentHash":"0100cdc8a57a05ba6b8d5b2470a26b36713da4741d83ff4119d7a969512f7d1d","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:19102400","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":null,"locator":"https://pubmed.ncbi.nlm.nih.gov/19102400/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"0100cdc8a57a05ba6b8d5b2470a26b36713da4741d83ff4119d7a969512f7d1d","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"19102400","rawPayloadReference":"pubmed:19102400"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"a974d4ec95b956fda4f05b712070ec3b","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16984988/","evidenceTier":"phase_1_2","summary":"Despite a strong rationale for trials of somatostatin analogs in the treatment of Graves' ophthalmopathy (GO), recent studies have provided conflicting results.","authors":"Marius N Stan, James A Garrity, Elizabeth A Bradley, John J Woog, Mark M Bahn, Michael D Brennan, Sandra C Bryant, Sara J Achenbach, Rebecca S Bahn","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2006,"doi":"10.1210/jc.2006-1105","pubmedId":"16984988","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2006-1105","sourceIdentityId":"926582b9a71aabd65cad40d4d75639b1","sourceStatus":"active","sourceContentHash":"40a37fe2b2170a34fbd18669e6d774ad63c9f09dc3b64a92750e211585f5fcd2","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:16984988","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2006-1105","locator":"https://pubmed.ncbi.nlm.nih.gov/16984988/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"40a37fe2b2170a34fbd18669e6d774ad63c9f09dc3b64a92750e211585f5fcd2","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"16984988","rawPayloadReference":"pubmed:16984988"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"efb94d29c718f74f0b40ae4d1c524c20","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16234004/","evidenceTier":"phase_1_2","summary":"The effect of octreotide plus interferon-alpha versus octreotide monotherapy on the primary study end points of time to treatment failure (progression, death, stop of study treatment) and long-term survival was investigated in patients with progressive metastatic neuroendocrine foregut (mainly pancreatic) and midgut tumors.","authors":"Rudolf Arnold, Anja Rinke, Klaus-Jochen Klose, Hans-Helge Müller, Matthias Wied, Karin Zamzow, Christina Schmidt, Carmen Schade-Brittinger, Peter Barth, Roland Moll, Michael Koller, Michael Unterhalt","publishingOrg":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","publicationYear":2005,"doi":"10.1016/s1542-3565(05)00481-7","pubmedId":"16234004","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s1542-3565(05)00481-7","sourceIdentityId":"150dd7ec43ca2ca788fa443bfd663be5","sourceStatus":"active","sourceContentHash":"65b71e6464f39096af19aecf5380880b46d6d28b4bd0770d2cb296e55b96517e","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:16234004","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/s1542-3565(05)00481-7","locator":"https://pubmed.ncbi.nlm.nih.gov/16234004/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"65b71e6464f39096af19aecf5380880b46d6d28b4bd0770d2cb296e55b96517e","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"16234004","rawPayloadReference":"pubmed:16234004"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"4188f3d0ce520a42750da524ad1aeffc","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Octreotide in acute bleeding esophageal varices: a prospective randomized study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11100339/","evidenceTier":"phase_1_2","summary":"To assess the value of octreotide in the control of acute bleeding esophageal varices, in a prospective randomized study.","authors":"D S Freitas, C Sofia, J M Pontes, C Gregório, J P Cabral, P Andrade, A Rosa, E Camacho, M Ferreira, F Portela, J M Romãozinho, L Tomé","publishingOrg":"Hepato-gastroenterology","publicationYear":2000,"doi":null,"pubmedId":"11100339","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:11100339","sourceIdentityId":"d70c1692dec0c809b24b449182c87d45","sourceStatus":"active","sourceContentHash":"925579b7f8fe256b55920af79232a04cc98fb40855180a432a4bae9ec03de0eb","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:11100339","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":null,"locator":"https://pubmed.ncbi.nlm.nih.gov/11100339/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"925579b7f8fe256b55920af79232a04cc98fb40855180a432a4bae9ec03de0eb","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"11100339","rawPayloadReference":"pubmed:11100339"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"14660c2098f78daa94a67d8bf3d494ba","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/10080605/","evidenceTier":"phase_1_2","summary":"Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily.","authors":"J Rubin, J Ajani, W Schirmer, A P Venook, R Bukowski, R Pommier, L Saltz, P Dandona, L Anthony","publishingOrg":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","publicationYear":1999,"doi":"10.1200/jco.1999.17.2.600","pubmedId":"10080605","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1200/jco.1999.17.2.600","sourceIdentityId":"01ad393bd00881eeb9adc08f064f4854","sourceStatus":"active","sourceContentHash":"b7ce6583bb9f1d9a9fa1b26b2c33af88667976f5cc827ee609492af626806e9c","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:10080605","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1200/JCO.1999.17.2.600","locator":"https://pubmed.ncbi.nlm.nih.gov/10080605/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"b7ce6583bb9f1d9a9fa1b26b2c33af88667976f5cc827ee609492af626806e9c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"10080605","rawPayloadReference":"pubmed:10080605"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"200a292db4800733d81057d0e0a465de","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/9127169/","evidenceTier":"phase_1_2","summary":"In this study, octreotide was not found to be of benefit in the treatment of acute pancreatitis.","authors":"C McKay, J Baxter, C Imrie","publishingOrg":"International journal of pancreatology : official journal of the International Association of Pancreatology","publicationYear":1997,"doi":"10.1007/bf02785915","pubmedId":"9127169","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/bf02785915","sourceIdentityId":"c96e8ca2f50c5ecdbcb64c8c9436e486","sourceStatus":"active","sourceContentHash":"b35d3fb2c50916aa95f4ea774c31670c1c835374a9c96f4d8fd731c6d4135441","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:9127169","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/BF02785915","locator":"https://pubmed.ncbi.nlm.nih.gov/9127169/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"b35d3fb2c50916aa95f4ea774c31670c1c835374a9c96f4d8fd731c6d4135441","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"9127169","rawPayloadReference":"pubmed:9127169"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"79df89f384bc264f65c1c474ab213a7f","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/7593435/","evidenceTier":"phase_1_2","summary":"Treatment of acromegaly with intermittent sc injections of octreotide is associated with an increased incidence of cholelithiasis.","authors":"J P Tauber, M F Poncet, A G Harris, H R Barthel, C Simonetta-Chateauneuf, L Buscail, F Bayard","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":1995,"doi":"10.1210/jcem.80.11.7593435","pubmedId":"7593435","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jcem.80.11.7593435","sourceIdentityId":"ee7ae974c4c9fba51706908684851f9e","sourceStatus":"active","sourceContentHash":"ed63b94720606f40f04b254a71ba1b1d999a63879be4a7fe3f38e4ddf6afb72e","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:7593435","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jcem.80.11.7593435","locator":"https://pubmed.ncbi.nlm.nih.gov/7593435/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"ed63b94720606f40f04b254a71ba1b1d999a63879be4a7fe3f38e4ddf6afb72e","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"7593435","rawPayloadReference":"pubmed:7593435"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"},{"id":"cb07f58332114c04aecff1d4e94fd109","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","title":"Octreotide treatment of acromegaly. A randomized, multicenter study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/1416572/","evidenceTier":"phase_1_2","summary":"To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly.","authors":"S Ezzat, P J Snyder, W F Young, L D Boyajy, C Newman, A Klibanski, M E Molitch, A E Boyd, L Sheeler, D M Cook","publishingOrg":"Annals of internal medicine","publicationYear":1992,"doi":"10.7326/0003-4819-117-9-711","pubmedId":"1416572","jurisdiction":null,"dateAccessed":"2026-09-09T22:53:32.826Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Octreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.7326/0003-4819-117-9-711","sourceIdentityId":"c9d7e79ff36f529b0301c5e375490172","sourceStatus":"active","sourceContentHash":"873fe3a0e1dddf8b28b7ebfc05099a4800353514fe8707275d490c80fb9a9d06","sourceVersion":1,"retrievedAt":"2026-09-09T22:53:32.826Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:1416572","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.7326/0003-4819-117-9-711","locator":"https://pubmed.ncbi.nlm.nih.gov/1416572/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"873fe3a0e1dddf8b28b7ebfc05099a4800353514fe8707275d490c80fb9a9d06","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"1416572","rawPayloadReference":"pubmed:1416572"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:53:32.826Z","updatedAt":"2026-09-09T22:55:49.819Z"}],"regulatory":[{"id":"386785029bae69e46b1e9cb6c640dce4","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","jurisdiction":"United States (FDA — MYCAPSSA)","status":"approved","approvedIndication":"MYCAPSSA octreotide delayed-release capsules are FDA-approved for long-term maintenance treatment in acromegaly patients who responded to and tolerated octreotide or lanreotide, according to current labeling.","rationale":"This oral product has formulation- and administration-specific absorption, interaction, eligibility, and monitoring requirements. Its authorization does not make oral and injectable products interchangeable or authorize other investigated uses.","sourceTitle":"FDA Drugs@FDA — MYCAPSSA NDA 208232","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208232","dateChecked":"2026-09-09T22:54:49.060Z","reviewDueAt":"2026-12-08T22:54:49.060Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-09T22:54:49.060Z","updatedAt":"2026-09-09T22:55:49.827Z"},{"id":"0171842049517b41f7b7f0c59403684b","peptideId":"2d3626df-2eb8-457e-b20c-2bf48972aa17","jurisdiction":"United States (FDA — SANDOSTATIN LAR DEPOT)","status":"approved","approvedIndication":"SANDOSTATIN LAR DEPOT is FDA-approved for long-term maintenance treatment in acromegaly after response and tolerance to subcutaneous octreotide, and for long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors, under current label criteria.","rationale":"Authorization is formulation-, route-, population-, and indication-specific. Current labeling controls prerequisite exposure, dosing, gallbladder, glucose, thyroid, cardiac, interaction, and monitoring requirements.","sourceTitle":"FDA Drugs@FDA — SANDOSTATIN LAR DEPOT NDA 021008","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021008","dateChecked":"2026-09-09T22:54:49.060Z","reviewDueAt":"2026-12-08T22:54:49.060Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-09T22:54:49.060Z","updatedAt":"2026-09-09T22:55:49.827Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}